Ronacaleret, formerly known as SB751689, is an orally -active calcium-sensing receptor (CaSR) antagonist that has the potential for therapeutic utility in the stimulation of PTH release, notably as a bone anabolic agent comparable to recombinant human PTH(1-34) (rhPTH(1-34)). Administration of ronacaleret led to lower peak levels of PTH than were observed with rhPTH(1-34), however, greater total PTH exposure was observed. References: Takenaka T, Inoue T, Miyazaki T, Nishiyama A, Ishii N, Hayashi M, Suzuki H. Antialbuminuric actions of calcilytics in the remnant kidney. Am J Physiol Renal Physiol. 2015 Aug 1;309(3):F216-26. doi: 10.1152/ajprenal.00003.2015. Epub 2015 May 27. PubMed PMID: 26017971.

纯度：≥98%

CAS：702686-96-2